| Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides -> Monitor Keywords |
|
|
 
Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptidesRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Enzyme Or Coenzyme Containing, Hydrolases (3. ) (e.g., Urease, Lipase, Asparaginase, Muramidase, Etc.), Acting On Peptide Bonds (3.4) (e.g., Urokinease, Etc.), Serene Proteinases (3.4.21) (e.g., Trypsin, Chymotrypsin, Plasmin, Thrombin, Elastase, Kallikrein, Fibrinolysin, Streptokinease, Etc.)Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20080069810, Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides. Brief Patent Description - Full Patent Description - Patent Application Claims
CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This patent application is a Divisional of copending U.S. application Ser. No. 10/290,814 filed Nov. 8, 2002 notice of Allowance mailed Jun. 29, 2007). This patent application claims the benefit of U.S. Provisional Patent Application No. 60/333,672 filed Nov. 27, 2001 and Danish Patent Application No. PA 2001 01664, filed Nov. 9, 2001. FIELD OF THIS INVENTION [0002] The present invention relates to a pharmaceutical composition comprising factor VII or a factor VII-related polyp eptide and TAFI or a TAFI-related polyp eptide. The invention also relates to the use of a combination of a factor VII or a factor VII-related polyp eptide and a TAFI or a TAFI-related polyp eptide for the manufacture of a medicament for treatment of subjects suffering from bleeding episodes, or prevention hereof. The invention also relates to a method for treatment of bleeding episodes in subjects and to a method for enhancing clot formation in a subject. The present invention also relates to kits comprising these compounds. BACKGROUND OF THE INVENTION [0003] Haemostasis is initiated by the formation of a complex between tissue factor (TF) being exposed to the circulating blood following an injury to the vessel wall, and FVIla which is present in the circulation in an amount corresponding to about 1% of the total FVII protein mass. This complex is anchored to the TF-bearing cell and activates FX into FXa and FIX into FIXa on the cell surface. FXa activates prothrombin to thrombin, which activates FVIII, FV, FXI and FXIII. Furthermore, the limited amount of thrombin formed in this initial step of haemostasis also activates the platelets. Following the action of thrombin on the platelets these change shape and expose charged phospholipids on their surface. This activated platelet surface forms the template for the further FX activation and the full thrombin generation. The further FX activation on the activated platelet surface occurs via a FIXa-FVIIla complex formed on the surface of the activated platelet, and FXa then converts prothrombin into thrombin while still on the surface. Thrombin then converts fibrinogen into fibrin which is insoluble and which stabilizes the initial platelet plug. This process is compartmentalized, i.e., localised to the site of TF expression or exposure, thereby minimizing the risk of a systemic activation of the coagulation system. The insoluble fibrin forming the plug is furthermore stabilised by FXIII-catalysed cross-linking of the fibrin fibres. [0004] FVIIa exists in plasma mainly as a single-chain zymogen, which is cleaved by FXa into its two-chain, activated form, FVIIa. Recombinant activated factor VIla (rFVIIa) has been developed as a pro-haemostatic agent. The administration of rFVIIa offers a rapid and highly effective pro-haemostatic response in haemophilic subjects with bleedings who cannot be treated with coagulation factor products due to antibody formation. Also bleeding subjects with a factor VII deficiency or subjects having a normal coagulation system but experiencing excessive bleeding can be treated successfully with FVIIa. In these studies, no unfavourable side effects of rFVIIa (in particular the occurrence of thromboembolism) has been encountered. [0005] Extra exogenously administered FVIIa increases the formation of thrombin on the activated platelet surface. This occurs in haemophiliac subjects lacking FIX or FVIII and therefore missing the most potent pathway for full thrombin formation. Also in the presence of a lowered number of platelets or platelets with a defect function, extra FVIIa increases the thrombin formation. [0006] Commercial preparations of recombinant human FVIIa are sold as NovoSeven.quadrature.Novo Nordisk A/S, Denmark). Novoseven.quadrature. is indicated for treatment of bleeding episodes in haemophilia A and B patients. Novoseven.quadrature. is the only recombinant FVIIa available on the market for effective and reliable treatment of bleeding episodes. [0007] Thrombin-activatable-fibrinolysis-inhibitor (TAFI) is a plasma carboxypeptidase with specificity for carboxyl-terminal arginine and lysine residues that acts as a potent inhibitor of fibrinolysis (Nesheim et al., Thromb. Haemost. 78:386, 1997). It is identical to the previously cloned plasma carboxypeptidase B (Eaton et al., J. Biol. Chem 269:21833, 1991) and the previously isolated carboxypeptidase U (Wang et al., J. Biol. Chem. 269:15937, 1994). This single chain 60.000 M polypeptide circulates in plasma at concentrations of about 70 nM (Bajzar et al., Blood 88:2093, 1997), and undergoes limited proteolysis in the presence of thrombin, which leads to its activation. The active carboxypeptidase, activated TAFI (TAFIa), catalyzes the removal of carboxy-terminal lysines and arginines, in the context of a fibrin clot. Since these residues are essential for the assembly of the fibrinolytic proteins, their removal down-regulates fibrinolysis. [0008] It is well known that subjects who bleed excessively in association with surgery or major trauma and need blood transfusions develop more complications than those who do not experience any bleeding. However, also moderate bleedings requiring the administration of human blood or blood products (latelets, leukocytes, plasma-derived concentrates for the treatment of coagulation defects, etc.) may lead to complications associated with the risk of transferring human viruses (hepatitis, HIV, parvovirus, and other, by now unknown viruses). Extensive bleedings requiring massive blood transfusions may lead to the development of multiple organ failure including impaired lung and kidney function. Once a subject has developed these serious complications a cascade of events involving a number of cytokines and inflammatory reactions is started making any treatment extremely difficult and unfortunately often unsuccessful. Therefore a major goal in surgery as well as in the treatment of major tissue damage is to avoid or minimise the bleeding. To avoid or minimise such bleeding it is of importance to ensure the formation of stable and solid haemostatic plugs that are not easily dissolved by fibrinolytic enzymes. Furthermore, it is of importance to ensure quick and effective formation of such plugs or clots. [0009] Today, subjects experiencing bleeding episodes, including trauma victims and subjects bleeding in association with surgery, are often treated with several injections or infusions of FVIIa since the short half-life of FVIIa (2.5 hours) may require more than one administration to maintain a certain level of haemostatic ability. A faster arrest of bleedings would be an important benefit to such subjects. So would a reduction in the number of administrations needed to stop bleeding and maintain haemostasis. [0010] European Patent No. 225.160 (Novo Nordisk) concerns compositions of FVIIa and methods for the treatment of bleeding disorders not caused by clotting factor defects or clotting factor inhibitors. [0011] European Patent No. 82.182 (Baxter Travenol Lab.) concerns a composition of factor Vlla for use in counteracting deficiencies of blood clotting factors or the effects of inhibitors to blood clotting factors in a subject. [0012] International Patent Publication No. WO 93/06855 (Novo Nordisk) concerns the topical application of FVIIa. [0013] U.S. Pat. Nos. 5,206,161, 5,364,934, and 5,593,674 concern isolated monomeric human carboxypeptidase B (PCPB), expression vector and host cell for making PCPB, and a method for coagulating blood comprising adding PCPB to the blood. [0014] There is still a need in the art for improved treatment of subjects experiencing bleeding episodes, including subjects where the bleeding episodes are due to surgery, trauma, or other forms of tissue damage; induced coagulophathy, including coagulopathy in multi-transfused subjects; congenital or acquired coagulation or bleeding disorders, including diminished liver function ("liver disease"); defective platelet function or decreased platelet number; lacking or abnormal essential clotting "compounds" (e.g., platelets or von Willebrand factor protein); increased fibrinolysis; anticoagulant therapy or thrombolytic therapy; or stem cell transplantation. [0015] There remains a need in the art for an improved, reliable and widely applicable method of enhancing coagulation, enhancing or ensuring formation of stable haemostatic plugs, or enhancing convenience for the treated subject, or achieving full haemostasis in subjects, in particular in subjects having an impaired thrombin generation. There is also a need for methods wherein the time to bleeding arrest is shortened. SUMMARY OF THE INVENTION [0016] One object of the present invention is to provide compositions, which can effectively be used in the treatment or prophylaxis of bleeding episodes and coagulation disorders. [0017] A second object of the present invention is to provide compositions in single-unit dosage form, which can effectively be used in the treatment or prophylaxis of bleeding episodes or as a procoagulant. Another object of the present invention is to provide compositions, methods of treatment or kits exhibiting a synergistic effect. [0018] A further object of the present invention is to provide compositions, methods of treatment or kits exhibiting no substantial side effects, such as a high level of systemic activation of the coagulation system. [0019] Other objects of the present invention will become apparent upon reading the present description. [0020] In a first aspect the invention provides a pharmaceutical composition comprising factor VII or a factor VII-related polypeptide, and TAFI or a TAFI-related polypeptide. Continue reading about Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides... Full patent description for Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides or other areas of interest. ### Previous Patent Application: Compositions and methods for the diagnosis and treatment of cancer Next Patent Application: Fsh and fsh receptor modulator compositions and methods for inhibiting osteclastic bone resorption and bone loss in osteoporosis Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides patent info. IP-related news and info Results in 0.12659 seconds Other interesting Feshpatents.com categories: Medical: Surgery , Surgery(2) , Surgery(3) , Drug , Drug(2) , Prosthesis , Dentistry 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
